Floatz logo

Adefovir Dipivoxil

Hepatitis B, Chronic

Asian-Pacific Alliance of Liver Disease, BeijingSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Hepatitis B, Chronic cohort.

Asset / SponsorPhaseRating
Lamivudine
Yonsei University
Phase 4BBB
Entecavir
Beijing Continent Pharmaceutical Co, Ltd.
Phase 4BBB
Telbivudine
The Fifth People's Hospital of Suzhou
Phase 4BBB
TENOFOVIR DISOPROXIL FUMARATE
Ningbo No.2 Hospital
Phase 4BBB
Tenofovir Alafenamide
Ningbo No.2 Hospital
Phase 4BB

View all 29 →

Same molecule, other indications

Adefovir Dipivoxil is also rated in:

cirrhosis of liverDormant
BB
Indicative ·
66 / 100
View asset →
acute liver failureDormant
D
Indicative ·
30 / 100
View asset →
hepatitis B virus infectionDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →